Alvotech(ALVOW)
LUXEMBOURG, LuxembourgBiotechnology
Focus: Alvotech is a publicly traded biosimilar-focused biotech company headquartered in Luxembourg, developing high-value TNF inhibitor and other biologic copies across immunology, neurology, gastroenterology, and ophthalmology.
Profile data last refreshed 1h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
12+6 this month
Growing — net +6 jobs in 30d
26 jobs added vs 20 removed. Steady team buildout.
Should You Work at Alvotech?
AI assessmentA biosimilar specialist for regulatory, manufacturing, and clinical professionals willing to accept modest hiring and transparency concerns in exchange for late-stage portfolio visibility.
Why Work Here
- Two marketed biosimilars (SIMLANDI, SELARSDI) generating revenue across high-prevalence indications (rheumatoid arthritis, Crohn's, psoriasis)
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Late-stage
14 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Growing
Jobs increasing
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
Growth
Lead marketed product targeting TNF-alpha across three large immunology indications with established unmet need.
Help build intelligence for Alvotech
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.